Thrombin-Activatable Fibrinolysis Inhibitor Antigen Levels and Cardiovascular Risk Factors
- 1 September 2000
- journal article
- other
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 20 (9) , 2156-2161
- https://doi.org/10.1161/01.atv.20.9.2156
Abstract
—Thrombin-activatable fibrinolysis inhibitor (TAFI) is a recently described fibrinolysis inhibitor that circulates in plasma as a procarboxypeptidase and is converted into an active form du...Keywords
This publication has 19 references indexed in Scilit:
- A Novel Approach to Arterial ThrombolysisBlood, 1999
- Performance of the platelet function analyser PFA-100?? in testing abnormalities of primary haemostasisBlood Coagulation & Fibrinolysis, 1999
- A Study of the Mechanism of Inhibition of Fibrinolysis by Activated Thrombin-activable Fibrinolysis InhibitorJournal of Biological Chemistry, 1998
- Activation of Thrombin-activable Fibrinolysis Inhibitor Requires Epidermal Growth Factor-like Domain 3 of Thrombomodulin and Is Inhibited Competitively by Protein CJournal of Biological Chemistry, 1998
- Plasma and Recombinant Thrombin-activable Fibrinolysis Inhibitor (TAFI) and Activated TAFI Compared with Respect to Glycosylation, Thrombin/Thrombomodulin-dependent Activation, Thermal Stability, and Enzymatic PropertiesPublished by Elsevier ,1998
- Both Cellular and Soluble Forms of Thrombomodulin Inhibit Fibrinolysis by Potentiating the Activation of Thrombin-activable Fibrinolysis InhibitorJournal of Biological Chemistry, 1998
- TAFI, or Plasma Procarboxypeptidase B, Couples the Coagulation and Fibrinolytic Cascades through the Thrombin-Thrombomodulin ComplexPublished by Elsevier ,1996
- Plasma carboxypeptidases as regulators of the plasminogen system.Journal of Clinical Investigation, 1995
- Purification and Characterization of TAFI, a Thrombin-activable Fibrinolysis InhibitorJournal of Biological Chemistry, 1995
- Fibrinogen as a Cardiovascular Risk FactorAnnals of Internal Medicine, 1993